Committed to sharing our science

Committed to sharing our science

412 results available

The Influence of QRS Duration and Resynchronization Status on the Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction: The GALACTIC-HF Trial

Oral Presentation, ESC-HFA 2026

Ruppert, M et al.

May 10, 2026
Dose-Dependent Effects of Aficamten Compared With Metoprolol in Obstructive HCM: The MAPLE-HCM Study

Oral Presentation, ESC-HFA 2026

Masri, A et al.

May 11, 2026
Favorable Effect of Aficamten on Left Atrial Mechanics in Obstructive Hypertrophic Cardiomyopathy: Insights from the SEQUOIA-HCM Trial

Oral Presentation, ESC-HFA 2026

Hamatani, Y et al.

May 9, 2026
No Increase in Arrhythmia Burden Following Aficamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Extended Ambulatory Electrocardiogram Analysis From FOREST-HCM

Poster, ESC-HFA 2026

Rowin, EJ et al.

May 11, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients

The American Journal of Cardiology

Veselka, J et al.

April 17, 2026